NATR vs. VRCA, VSTM, CMRX, FBIO, HLF, USNA, NUS, MED, VERU, and EL
Should you be buying Nature's Sunshine Products stock or one of its competitors? The main competitors of Nature's Sunshine Products include Verrica Pharmaceuticals (VRCA), Verastem (VSTM), Chimerix (CMRX), Fortress Biotech (FBIO), Herbalife (HLF), USANA Health Sciences (USNA), Nu Skin Enterprises (NUS), Medifast (MED), Veru (VERU), and Estée Lauder Companies (EL).
Verrica Pharmaceuticals (NASDAQ:VRCA) and Nature's Sunshine Products (NASDAQ:NATR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, community ranking, media sentiment, valuation and risk.
Verrica Pharmaceuticals has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500. Comparatively, Nature's Sunshine Products has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500.
Verrica Pharmaceuticals received 2 more outperform votes than Nature's Sunshine Products when rated by MarketBeat users. Likewise, 64.94% of users gave Verrica Pharmaceuticals an outperform vote while only 62.89% of users gave Nature's Sunshine Products an outperform vote.
Verrica Pharmaceuticals presently has a consensus price target of $13.50, indicating a potential upside of 65.04%. Nature's Sunshine Products has a consensus price target of $24.00, indicating a potential upside of 59.57%. Given Nature's Sunshine Products' higher possible upside, equities research analysts clearly believe Verrica Pharmaceuticals is more favorable than Nature's Sunshine Products.
Nature's Sunshine Products has higher revenue and earnings than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Nature's Sunshine Products, indicating that it is currently the more affordable of the two stocks.
Nature's Sunshine Products has a net margin of 3.69% compared to Nature's Sunshine Products' net margin of -905.83%. Verrica Pharmaceuticals' return on equity of 10.59% beat Nature's Sunshine Products' return on equity.
42.5% of Verrica Pharmaceuticals shares are held by institutional investors. Comparatively, 79.4% of Nature's Sunshine Products shares are held by institutional investors. 42.6% of Verrica Pharmaceuticals shares are held by company insiders. Comparatively, 4.7% of Nature's Sunshine Products shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, Nature's Sunshine Products' average media sentiment score of 0.00 equaled Verrica Pharmaceuticals'average media sentiment score.
Summary
Nature's Sunshine Products beats Verrica Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
Get Nature's Sunshine Products News Delivered to You Automatically
Sign up to receive the latest news and ratings for NATR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NATR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nature's Sunshine Products Competitors List
Related Companies and Tools
